Sionna Therapeutics (SION) Cash from Financing Activities (2024 - 2026)

Sionna Therapeutics (SION) has 3 years of Cash from Financing Activities data on file, last reported at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 99.06% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 97.39% YoY), and the FY2025 full-year result was $205.7 million, up 14.94% from the prior year.
• Cash from Financing Activities improved to $1.9 million in Q1 2026, from $1.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $202.4 million in Q1 2025 to a low of -$1.4 million in Q4 2024.
• A 3-year average of $43.0 million and a median of $1.7 million in 2025 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 298.19% in 2025, while the deepest fall reached 921.05% in 2025.
• Tracing SION's Cash from Financing Activities over 3 years: stood at -$1.4 million in 2024, then jumped by 217.83% to $1.7 million in 2025, then gained by 14.1% to $1.9 million in 2026.
• Business Quant data shows SION's Cash from Financing Activities at $1.9 million in Q1 2026, $1.7 million in Q4 2025, and $2.0 million in Q3 2025.